Drug shows revolutionary results in extending life for tough-to-treat breast cancer
New data released Saturday at the 2021 European Society of Medical Oncology conference is garnering excitement for those seeking to battle some of the most challenging forms of breast cancer.
Researchers found using the antibody conjugate drug ENHERTU to treat currently incurable HER-2-positive breast cancer was significantly more successful at reducing tumor size and keeping the patient alive longer without progression of disease than the current standard of care TDM1.
Comments